Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125276201 | 12527620 | 1 | I | 20160620 | 20160705 | 20160705 | EXP | US-IPCA LABORATORIES LIMITED-IPC201606-000546 | IPCA | WEISBERG L. LACTIC ACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES MELLITUS. CLIN J AM SOC NEPHROL 2015 AUG 07;10(8):1476-83. | 49.00 | YR | M | Y | 0.00000 | 20160705 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125276201 | 12527620 | 1 | PS | METFORMIN HYDROCHLORIDE. | METFORMIN HYDROCHLORIDE | 1 | 78422 | ||||||||||||
125276201 | 12527620 | 2 | SS | METFORMIN HYDROCHLORIDE. | METFORMIN HYDROCHLORIDE | 1 | 78422 | ||||||||||||
125276201 | 12527620 | 3 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | 78010 | 40 | MG | ||||||||||
125276201 | 12527620 | 4 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | 78010 | 80 | MG | BID | |||||||||
125276201 | 12527620 | 5 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Intravenous (not otherwise specified) | 78010 | 160 | MG | |||||||||
125276201 | 12527620 | 6 | SS | EPINEPHRINE. | EPINEPHRINE | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
125276201 | 12527620 | 7 | SS | NOREPINEPHRINE | NOREPINEPHRINENOREPINEPHRINE BITARTRATE | 1 | Intravenous (not otherwise specified) | 0 | |||||||||||
125276201 | 12527620 | 8 | C | Insulin | INSULIN NOS | 1 | 0 | ||||||||||||
125276201 | 12527620 | 9 | C | DIGOXIN. | DIGOXIN | 1 | 0 | ||||||||||||
125276201 | 12527620 | 10 | C | Warfarin | WARFARIN | 1 | 0 | ||||||||||||
125276201 | 12527620 | 11 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 0 | ||||||||||||
125276201 | 12527620 | 12 | C | METOPROLOL SUCCINATE. | METOPROLOL SUCCINATE | 1 | 0 | ||||||||||||
125276201 | 12527620 | 13 | C | METOLAZONE. | METOLAZONE | 1 | 0 | 2.5 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125276201 | 12527620 | 1 | Type 2 diabetes mellitus |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125276201 | 12527620 | DE |
125276201 | 12527620 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125276201 | 12527620 | Lactic acidosis | |
125276201 | 12527620 | Metabolic acidosis | |
125276201 | 12527620 | Metabolic alkalosis | |
125276201 | 12527620 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |